

James W Murrough

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/615471/publications.pdf>

Version: 2024-02-01

151
papers

14,732
citations

28736

57
h-index

23173

116
g-index

162
all docs

162
docs citations

162
times ranked

14937
citing authors

#	ARTICLE	IF	CITATIONS
1	A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City. <i>International Archives of Occupational and Environmental Health</i> , 2022, 95, 1279-1291.	1.1	20
2	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. <i>Translational Psychiatry</i> , 2022, 12, 12.	2.4	14
3	The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants. <i>CNS Drugs</i> , 2022, 36, 207-216.	2.7	12
4	Association Between Depression and Severity of Dry Eye Symptoms, Signs, and Inflammatory Markers in the DREAM Study. <i>JAMA Ophthalmology</i> , 2022, 140, 392.	1.4	22
5	The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. <i>Journal of Affective Disorders</i> , 2022, , .	2.0	0
6	Beyond the neuron: Role of non-neuronal cells in stress disorders. <i>Neuron</i> , 2022, 110, 1116-1138.	3.8	18
7	Pharmacological Treatments for Anhedonia. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 467-489.	0.8	4
8	Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder. <i>Translational Psychiatry</i> , 2022, 12, 209.	2.4	12
9	Exaggerated amygdala response to threat and association with immune hyperactivity in depression. <i>Brain, Behavior, and Immunity</i> , 2022, 104, 205-212.	2.0	7
10	Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. <i>Molecular Psychiatry</i> , 2021, 26, 5140-5149.	4.1	59
11	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 383-391.	1.0	28
12	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 151-157.	2.0	6
13	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2021, 35, 124-127.	2.0	2
14	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , 2021, 178, 193-202.	4.0	122
15	Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls. <i>Frontiers in Psychiatry</i> , 2021, 12, 662963.	1.3	0
16	Transdiagnostic Psychiatric Symptoms, Burnout, and Functioning in Frontline Health Care Workers Responding to the COVID-19 Pandemic. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	15
17	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270
18	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 437-446.	4.0	33

#	ARTICLE	IF	CITATIONS
19	Vortioxetine Versus Placebo for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	16
20	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Focus (American J Psychiatry)</i> , 2021, 129, 1010-1019.	6.4	9
21	Moral distress in frontline healthcare workers in the initial epicenter of the COVID-19 pandemic in the United States: Relationship to PTSD symptoms, burnout, and psychosocial functioning. <i>Depression and Anxiety</i> , 2021, 38, 1007-1017.	2.0	86
22	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. <i>Neuropsychopharmacology</i> , 2021, 46, 2266-2277.	2.8	19
23	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. <i>Depression and Anxiety</i> , 2021, 38, 1108-1119.	2.0	6
24	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. <i>Journal of Medical Internet Research</i> , 2021, 23, e31295.	2.1	15
25	Psychological Impact of the COVID-19 Pandemic on Frontline Health Care Workers During the Pandemic Surge in New York City. <i>Chronic Stress</i> , 2021, 5, 247054702097789.	1.7	65
26	Intrasubject functional connectivity related to self-generated thoughts. <i>Brain and Behavior</i> , 2021, 11, e01860.	1.0	2
27	Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. <i>Translational Psychiatry</i> , 2021, 11, 565.	2.4	27
28	Effects of Sleep, Exercise, and Leadership Support on Resilience in Frontline Healthcare Workers During the COVID-19 Pandemic. <i>Journal of Occupational and Environmental Medicine</i> , 2021, Publish Ahead of Print, .	0.9	3
29	Chemical, Manufacturing, and Standardization Controls of Grape Polyphenol Dietary Supplements in Support of a Clinical Study: Mass Uniformity, Polyphenol Dosage, and Profiles. <i>Frontiers in Nutrition</i> , 2021, 8, 780226.	1.6	1
30	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	4.1	235
31	Effects of chronic physical disease and systemic inflammation on suicide risk in patients with depression: a hospital-based case-control study. <i>Psychological Medicine</i> , 2020, 50, 29-37.	2.7	20
32	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. <i>Molecular Psychiatry</i> , 2020, 25, 1323-1333.	4.1	40
33	Shared Neural Phenotypes for Mood and Anxiety Disorders. <i>JAMA Psychiatry</i> , 2020, 77, 172.	6.0	106
34	Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 696-710.	1.3	34
35	Neural correlates of rumination in major depressive disorder: A brain network analysis. <i>NeuroImage: Clinical</i> , 2020, 25, 102142.	1.4	62
36	Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 29-45.	1.3	126

#	ARTICLE	IF	CITATIONS
37	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 783-790.	1.0	23
38	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , 2020, 266, 615-620.	2.0	28
39	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , 2020, 11, 595584.	1.3	143
40	The role of the locus coeruleus in the generation of pathological anxiety. <i>Brain and Neuroscience Advances</i> , 2020, 4, 239821282093032.	1.8	102
41	Dissociating self-generated volition from externally-generated motivation. <i>PLoS ONE</i> , 2020, 15, e0232949.	1.1	6
42	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020, 45, 1656-1663.	2.8	50
43	Pharmacological Treatments for Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2020, 13, 116.	1.7	78
44	A randomized proof-of-mechanism trial applying the "fast-fail" approach to evaluating μ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020, 26, 760-768.	15.2	129
45	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. <i>Advances in Pharmacology</i> , 2020, 89, 163-194.	1.2	8
46	Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivo ultra-high field 7-Tesla MRI study. <i>NeuroImage: Clinical</i> , 2020, 25, 102148.	1.4	25
47	Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. <i>Neuropsychopharmacology</i> , 2020, 45, 975-981.	2.8	71
48	Efficacy of Esketamine Augmentation in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	71
49	High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. <i>Neuropsychopharmacology</i> , 2019, 44, 390-398.	2.8	19
50	Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. <i>Patient</i> , 2019, 12, 527-537.	1.1	9
51	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1140, 585-600.	0.8	5
52	116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective μ -Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. <i>Biological Psychiatry</i> , 2019, 85, S48-S49.	0.7	0
53	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , 2019, 3, 247054701987788.	1.7	2
54	The Neurobiology of Resilience: Complexity and Hope. <i>Biological Psychiatry</i> , 2019, 86, 406-409.	0.7	17

#	ARTICLE	IF	CITATIONS
55	132. Structural and Connectomic Brain Features of Treatment Resistant Depression and Antidepressant Response to Ketamine. <i>Biological Psychiatry</i> , 2019, 85, S55.	0.7	0
56	S8. Increased Locus Coeruleus Volume in Humans With Pathological Anxiety: An Ultra-High Field 7-Tesla MRI Study. <i>Biological Psychiatry</i> , 2019, 85, S299-S300.	0.7	0
57	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , 2019, 44, 1233-1238.	2.8	35
58	Neurobiology of Resilience: Interface Between Mind and Body. <i>Biological Psychiatry</i> , 2019, 86, 410-420.	0.7	175
59	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2019, 44, 1812-1819.	2.8	32
60	Screening and Management of Depression in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1827-1845.	1.2	182
61	Hippocampal subfield-specific connectivity findings in major depressive disorder: A 7 Tesla diffusion MRI study. <i>Journal of Psychiatric Research</i> , 2019, 111, 186-192.	1.5	14
62	Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla. <i>Translational Psychiatry</i> , 2019, 9, 94.	2.4	37
63	F124. Mapping the Neural Correlates of Mood and Anxiety Disorders Onto Research Domain Criteria: A Meta-Analysis of 226 Task-Related Functional Imaging Studies. <i>Biological Psychiatry</i> , 2019, 85, S261.	0.7	3
64	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. <i>Focus (American J Psychiatry)</i> , 2019, 117, 1038-1041.	0.4	1
65	Electroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. <i>Contemporary Clinical Trials</i> , 2019, 77, 19-26.	0.8	34
66	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 82-84.	21.5	52
67	Determinants and Predictive Value of Clinician Assessment of Short-Term Suicide Risk. <i>Suicide and Life-Threatening Behavior</i> , 2019, 49, 614-626.	0.9	30
68	New Mechanisms, New Opportunities. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	0
69	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , 2018, 230, 56-64.	2.0	36
70	T131. KNCQ Channel Opener Ezogabine_x000B_as a Treatment for Depression: A Preliminary Resting State fMRI Analysis. <i>Biological Psychiatry</i> , 2018, 83, S179.	0.7	0
71	86. Role of the Epigenetic Agent Acetyl-L-Carnitine as Gating Biomarker in Depression and Influences of Childhood Trauma. <i>Biological Psychiatry</i> , 2018, 83, S35-S36.	0.7	0
72	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , 2018, 175, 150-158.	4.0	476

#	ARTICLE	IF	CITATIONS
73	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018, 11, 75-84.	0.7	20
74	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	2.4	26
75	F142. Effect of Treatment Resistance Status on Whole Brain Voxel-Based Morphometry in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2018, 83, S293.	0.7	0
76	F163. Inflammation is Associated With Mesolimbic Reward Circuitry in Major Depression. <i>Biological Psychiatry</i> , 2018, 83, S302.	0.7	0
77	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , 2018, 1, .	5.7	16
78	Acetyl- L -carnitine deficiency in patients with major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8627-8632.	3.3	102
79	T129. Brain Connectivity Changes Associated With a Cognitive-Emotional Training Intervention for Depression. <i>Biological Psychiatry</i> , 2018, 83, S178.	0.7	0
80	65. From Stress Resilience to Novel Therapeutics: KCNQ Channel Openers and Other Approaches Emerging From Translational Neuroscience. <i>Biological Psychiatry</i> , 2018, 83, S27.	0.7	0
81	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 3-11.	1.0	56
82	Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. <i>Lancet, The</i> , 2017, 389, 834-845.	6.3	442
83	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , 2017, 218, 277-283.	2.0	41
84	Neuropeptide Y, resilience, and PTSD therapeutics. <i>Neuroscience Letters</i> , 2017, 649, 164-169.	1.0	62
85	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. <i>Translational Psychiatry</i> , 2017, 7, e1065-e1065.	2.4	135
86	Targeting glutamate signalling in depression: progress and prospects. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 472-486.	21.5	345
87	Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. <i>Human Brain Mapping</i> , 2017, 38, 6068-6082.	1.9	63
88	171. A Randomized Controlled Dose-Ranging Study of Intranasal Administration of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 81, S71.	0.7	1
89	871. Modulation of the Insula and Somatosensory Cortex by Ondansetron. <i>Biological Psychiatry</i> , 2017, 81, S352.	0.7	0
90	Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?. <i>Biological Psychiatry</i> , 2017, 82, 858-860.	0.7	13

#	ARTICLE	IF	CITATIONS
91	Prazosin during threat discrimination boosts memory of the safe stimulus. <i>Learning and Memory</i> , 2017, 24, 597-601.	0.5	12
92	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , 2017, 42, 1210-1219.	2.8	240
93	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , 2016, 37, 3214-3223.	1.9	125
94	Ketamine for treatment-resistant depression: recent developments and clinical applications: Table 1. <i>Evidence-Based Mental Health</i> , 2016, 19, 35-38.	2.2	102
95	Ketamine's Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies. , 2016, , 99-121.		1
96	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 816-826.	4.0	388
97	Ketamine for Depression: An Update. <i>Biological Psychiatry</i> , 2016, 80, 416-418.	0.7	17
98	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. <i>Nature Communications</i> , 2016, 7, 11671.	5.8	109
99	Cortical abnormalities and association with symptom dimensions across the depressive spectrum. <i>Journal of Affective Disorders</i> , 2016, 190, 529-536.	2.0	38
100	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. <i>Psychological Medicine</i> , 2015, 45, 3571-3580.	2.7	244
101	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. <i>Neuropsychopharmacology</i> , 2015, 40, 1084-1090.	2.8	117
102	Ketamine for Posttraumatic Stress Disorder—Reply. <i>JAMA Psychiatry</i> , 2015, 72, 95.	6.0	6
103	Emerging drugs for the treatment of anxiety. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 393-406.	1.0	102
104	“Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?” <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 383-393.	0.7	5
105	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 216-225.	0.6	18
106	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 47-58.	1.8	70
107	Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations. <i>Psychopharmacology</i> , 2015, 232, 1497-1499.	1.5	1
108	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , 2015, 5, e509-e509.	2.4	93

#	ARTICLE	IF	CITATIONS
109	Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 247-252.	1.1	179
110	Cerebellar Morphology and the Effects of Stimulant Medications in Youths with Attention Deficit-Hyperactivity Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 718-726.	2.8	59
111	Advances in Psychopharmacology for Anxiety Disorders. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 152-162.	0.4	13
112	COGNITIVE-EMOTIONAL TRAINING AS AN INTERVENTION FOR MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2014, 31, 699-706.	2.0	58
113	EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 335-343.	2.0	275
114	Attention Bias Variability and Symptoms of Posttraumatic Stress Disorder. <i>Journal of Traumatic Stress</i> , 2014, 27, 232-239.	1.0	145
115	Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. <i>JAMA Psychiatry</i> , 2014, 71, 681.	6.0	466
116	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , 2014, 231, 481-488.	1.5	73
117	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16136-16141.	3.3	545
118	Current Treatments for Anxiety and Obsessive-Compulsive Disorders. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 248-262.	0.7	2
119	In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. <i>Neuroscience Letters</i> , 2014, 569, 74-79.	1.0	45
120	A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2014, 76, 970-976.	0.7	369
121	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 331-336.	1.0	195
122	Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. <i>Biological Psychiatry</i> , 2013, 74, 250-256.	0.7	632
123	Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2013, 170, 1134-1142.	4.0	965
124	Novel glutamatergic drugs for the treatment of mood disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1101.	1.0	76
125	Ketamine for Treatment-Resistant Unipolar Depression. <i>CNS Drugs</i> , 2012, 26, 189-204.	2.7	203
126	Is There Anything Really Novel on the Antidepressant Horizon?. <i>Current Psychiatry Reports</i> , 2012, 14, 643-649.	2.1	59

#	ARTICLE	IF	CITATIONS
127	Neurobiology of resilience. <i>Nature Neuroscience</i> , 2012, 15, 1475-1484.	7.1	934
128	Positron Emission Tomography Shows Elevated Cannabinoid CB_1 Receptor Binding in Men with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 2104-2109.	1.4	53
129	CHAPTER 9. Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder. <i>RSC Drug Discovery Series</i> , 2012, , 226-257.	0.2	0
130	Ketamine as a Novel Antidepressant: From Synapse to Behavior. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 303-309.	2.3	147
131	ECT in Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2012, 169, 1238-1244.	4.0	208
132	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. <i>NMR in Biomedicine</i> , 2012, 25, 1073-1087.	1.6	134
133	The Serotonin Transporter and Emotionality: Risk, Resilience, and New Therapeutic Opportunities. <i>Biological Psychiatry</i> , 2011, 69, 510-512.	0.7	19
134	Reply to: Dose- and Exposure-Response to Ketamine in Depression. <i>Biological Psychiatry</i> , 2011, 70, e11-e12.	0.7	6
135	The Serotonin 1B Receptor: A New Target for Depression Therapeutics?. <i>Biological Psychiatry</i> , 2011, 69, 714-715.	0.7	15
136	Reduced Amygdala Serotonin Transporter Binding in Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2011, 70, 1033-1038.	0.7	79
137	Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , 2011, 96, 553-563.	1.0	264
138	A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>European Neuropsychopharmacology</i> , 2011, 21, 221-229.	0.3	44
139	Reduced ventral striatal/ventral pallidal serotonin $1B$ receptor binding potential in major depressive disorder. <i>Psychopharmacology</i> , 2011, 213, 547-553.	1.5	118
140	The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand Binding. <i>Archives of General Psychiatry</i> , 2011, 68, 892.	13.8	84
141	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. <i>Psychiatric Annals</i> , 2011, 41, 408-412.	0.1	4
142	A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 414-415.	1.1	37
143	Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. <i>NMR in Biomedicine</i> , 2010, 23, 643-650.	1.6	68
144	Cracking the moody brain: Lifting the mood with ketamine. <i>Nature Medicine</i> , 2010, 16, 1384-1385.	15.2	31

#	ARTICLE	IF	CITATIONS
145	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 71-82.	1.0	239
146	Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2010, 67, 139-145.	0.7	589
147	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. <i>Modern Problems of Pharmacopsychiatry</i> , 2010, , 89-100.	2.5	1
148	Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2009, 65, 792-800.	0.7	227
149	A Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2009, 66, 656-664.	0.7	209
150	Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal Subjects. <i>American Journal of Psychiatry</i> , 2006, 163, 1784-1790.	4.0	424
151	Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage. <i>Brain Research</i> , 2000, 883, 125-130.	1.1	8